Press releases
- Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
- ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
- EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
- AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
- Ascentage Pharma Announces 2023 Annual Results
- AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
More ▼
Key statistics
On Friday, Ascentage Pharma Group International (36X:DEU) closed at 2.00, 9.29% above its 52-week low of 1.83, set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.10 |
---|---|
High | 2.10 |
Low | 2.00 |
Bid | 2.04 |
Offer | 2.16 |
Previous close | 1.93 |
Average volume | 0.00 |
---|---|
Shares outstanding | 290.22m |
Free float | 212.90m |
P/E (TTM) | -- |
Market cap | 5.17bn HKD |
EPS (TTM) | -3.53 HKD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼